LC
Lynx1 Capital Management LP
内部人交易记录
其他基于 11 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Browse the complete record of transactions filed by Lynx1 Capital Management LP. Insider active across 5 companies, notably TScan Therapeutics, Inc.. Aggregated, 19 filings have been published. Split: 18 buys · 1 sell. Total volume traded: €11.1m. History available since 31 May 2023. The latest transaction was disclosed on 6 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Lynx1 Capital Management LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报19 总计
5,222 股@ US$11.39980.030% mcap70.6% 占其流量Common stock, $0.001 par value per shareSEC:0000902664-26-003434:0
1,462 股@ US$13.18690.0098% mcap22.9% 占其流量Common stock, $0.001 par value per shareSEC:0000902664-26-003434:1
520 股@ US$10.60100.0% 占其流量Common stock, $0.001 par value per shareSEC:0000902664-26-001845:0
80,069 股@ US$0.89893.7% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-005396:0
165,667 股@ US$8.400519.6% 占其流量Common stock, $0.0001 par value per shareSEC:0000902664-25-004662:0
639,110 股@ US$5.137100.0% 占其流量Common stock, $0.00001 par value per shareSEC:0000902664-25-004536:0
15,032 股@ US$7.5875.5% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-004499:0
51,500 股@ US$7.942719.5% 占其流量Common StockSEC:0000902664-25-004499:1
150,000 股@ US$8.85563.0% 占其流量Common StockSEC:0000902664-25-004499:2
32,217 股@ US$7.839512.0% 占其流量Common StockSEC:0000902664-25-004499:3
556,300 股@ US$6.4663.2% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-004379:0
325 股@ US$6.95580.4% 占其流量Common stock, $0.0001 par value per share (Common Stock)SEC:0000902664-25-004079:0
13,123 股@ US$5.436114.1% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-003152:0
1,388,794 股@ US$1.2092.6% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-002511:0
373,645 股@ US$0.645162.3% 占其流量Common stock, $0.0001 par value per shareSEC:0000902664-24-007075:0
31,800 股@ US$3.00725.7% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-24-006934:0
259,998 股@ US$0.564137.7% 占其流量Common stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-24-006799:0
947 股@ US$4.34420.2% 占其流量Common stock, $0.0001 par value per shareSEC:0000902664-24-006718:0
10,000 股@ US$2.51481.5% 占其流量Common stock, $0.0001 par value per share Common StockSEC:0000902664-23-003407:0
About Lynx1 Capital Management LP
Lynx1 Capital Management LP has filed 17 filings in total. In the 17 sampled recent filings, the reported transactions are mostly acquisitions, with buys of EUR 10993296 and sells of EUR 23513 between 2023-06-02 and 2026-04-02. The companies named in these filings are Cullinan Therapeutics, Inc., TScan Therapeutics, Inc., Passage BIO, Inc., Korro Bio, Inc., where the entity is listed as 10% Owner, and Neuphoria Therapeutics Inc.